Polypeptide With Localisation/Targeting Motif TRIZ Cases

Recombinant meganucleases target the beta-2 microglobulin gene to eliminate MHC class I expression, enabling off-the-shelf allogeneic CAR T cell production.

VCX/Y peptides and engineered receptors target tumor antigens, resolving the trade-off between therapeutic efficacy and tissue toxicity.

CAR-T cells targeting TAG-72 kill cancerous T cells while sparing normal cells, addressing limited remission rates and durability in CTCL treatment.

Segmenting Cas9 into two domains overcomes viral packaging limits, enabling efficient delivery and high target specificity.

Artificial secretion signal peptides direct heterologous protein export from Lactobacillus cells, resolving unpredictable natural peptide performance.

Dynamic perfusion fermentation separates cells from spent media to boost secretion rates up to 1.2 g/L/hr.

Stapled peptides inhibit HSV-1 DNA synthesis by targeting the processivity factor interaction, overcoming drug-resistant mutants.

Antennapedia-derived cell-penetrating peptides transport therapeutic proteins across cell membranes.

A tet operator-regulated CAR system modulates CSF1R targeting via doxycycline, preventing cytokine storms in Alzheimer's treatment.

SMAC mimetics modify the tumor microenvironment to sustain CAR T cell efficacy against refractory cancers by inducing apoptosis.

A Huntingtin-derived peptide sequence specifically inhibits caspase 6 enzymatic activity.

IL-10 fused to IgG Fc subunits forms stable heterodimers, extending serum half-life and reducing homodimer impurities for sustained antitumor efficacy.

Anti-NMDAR2B agents target NMDAR2B receptors to inhibit cancer growth, addressing limited targeting of this subtype in current immunotherapies.

Segmenting base editors into intein-fused halves bypasses AAV packaging limits, enabling efficient in vivo gene therapy.

Segmented fusion proteins prevent tonic signaling exhaustion in NK-CAR cells, sustaining anti-tumor immunity.

Engineered MetMAb-derived single-chain variable fragment directs chimeric antigen receptor T cells to target MET-expressing tumor cells.

Segmented chimeric antigen receptors target CD22-expressing cancer cells, reducing tumor burden and improving survival in preclinical models.

Recombinant chicken IgY antibodies detect human thymidine kinase 1 without cross-reacting with mammalian IgG or rheumatoid factors.

A DNA vaccine composition encodes Zika virus E protein domain III repeated three times to induce high antibody titers.

Replacing PBS with 5% human albumin in wash media reduces centrifugation stress, recovering over 80% of NK-92 cells with high viability.

Segmented T cell receptors recognize multiple TCL1 peptide epitopes to overcome tumor antigen loss and prevent relapse in B-cell malignancies.

A fusion protein uses the Lys2 CAD4a domain to anchor polypeptides on lactic acid bacteria surfaces without genetic modification.

Dual-target CAR-T cells require simultaneous binding to EGFR and MUC1, reducing on-target toxicities while enhancing anti-tumor activity.

A chimeric antigen receptor combines MSLN binding domains with additional tumor antigens to enhance targeted cell recognition.

Engineered chimeric antigen receptors target aberrantly glycosylated MUC1 to reduce off-target toxicity in solid tumors.

Reversible RiBns resolve the trade-off between reliable inhibition and structural analysis of malaria parasite enzymes.

Nanobody-OGT fusion proteins recruit glycan modifying enzymes to target proteins for selective O-GlcNAc modification.

Circularly permuted Cas9 variants resolve narrow editing windows and strict PAM requirements by expanding targeting scope while maintaining precision.

Genetically modified animals expressing human PD-1 proteins enable precise in vivo testing of therapeutic agents.

Y666A and Y677A mutations in Cas13f reduce spacer sequence-independent collateral cleavage to lower cytotoxicity.

Segmenting CAR T cell doses reduces cytokine release syndrome while maintaining therapeutic efficacy in hematological cancer treatment.

Disrupting Regnase 1, TGFBRII, TRAC, and beta-2 microglobulin genes overcomes limited T cell persistence in the tumor microenvironment.

A mitochondria-targeted polypeptide delivers active substances to tumor cells using lipophilic cationic groups and disulfide bonds.

Multispecific chimeric antigen receptors combine CD4 and CRD domains to target HIV envelope proteins on infected cells.

A carrier peptide fragment transfers foreign substances into eukaryotic cells via enhanced membrane permeability.

Psychrophilic Aliivibrio wodanis hosts prevent aggregation of cold-adapted enzymes, maintaining activity at low temperatures.

Modifying propeptide amino acid sequences at specific positions increases extracellular secretion efficiency of mature proteases in Bacillus host cells.

A hybrid promoter sequence combining MND and HTLV elements drives high gene expression in immune cells.

Adding a p38 inhibitor and SDF-1 to culture media overcomes low production efficiency of CD4/CD8 double-positive T cells from pluripotent stem cells.

An HBx deletion mutant fusion protein minimizes aggregation during refolding, improving vaccine yield without complex purification.

A switchable chimeric antigen receptor effector cell system uses a peptide neo-epitope to enable controlled activation and deactivation of T cells.

Fusing Talaromyces emersonii catalytic domains with Trichoderma reesei binding domains boosts fermentable sugar yields from lignocellulosic feedstocks.

Intratumoral lentiviral vectors expand immune cell populations in vivo, eliminating ex vivo culture time and cost.

Steroid acid-peptide conjugates bypass endosomal entrapment and degradation to deliver biological cargoes directly into the cytosol or nucleus.

Segmented CAR structures enable dual antigen targeting, reducing on-target off-tissue toxicity in ovarian cancer treatment.

Licensed NK cells resolve donor availability limits by targeting leukemia without requiring full HLA matching.

Segmenting connexin-43 into peptide sequence 266-275 improves membrane permeability and metabolic stability while maintaining antitumor efficacy.

Seven novel antibodies target mesothelin to enhance CAR-T cell specificity and efficacy against overexpressing cancer cells.